S. Korea eyes chip alliance with Netherlands
Suneung without 'killer questions' still not easy, results show
US defense policy bill calls for maintaining 28,500 US troops in Korea
Teens' excessive smartphone use linked to mental health risk: study
SK carries out complete reshuffle of top brass
S. Korea, US, Japan to discuss regional security issues: White House
Ruling party reform committee disbands early, says job half done
Auditor says Moon govt distorted 2020 death of fisheries official
Ex-justice minister's daughter attends forgery trial in college admissions scandal
Moon officials tried to cover up North Korea’s murder of South Korean: state inspectors
Celltrion’s COVID-19 treatment gets safety nod in AustraliaBy Kan Hyeong-woo
Published : Feb. 7, 2022 - 13:53
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
4 contentious bills scrapped in revote after Yoon's veto
S. Korea logs current account surplus for 6th month in October
Ex-Democratic Party chair denies bribery, illegal campaign allegations